Results 181 to 190 of about 686,579 (305)

N‐acetylcysteine for non‐paracetamol‐induced acute liver failure in children: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Non‐surgical treatment of acute liver failure (ALF) is primarily supportive and depends on the underlying cause. While N‐acetylcysteine (NAC) is proven effective in paracetamol‐induced ALF, its potential benefits in non‐paracetamol ALF for paediatric patients remain unclear.
Alise D. E. de Groot   +7 more
wiley   +1 more source

Operationalizing independent oversight in large-scale public health cohorts: Monitoring protocol for the NIMHANS-NH-SKAN Stroke project. [PDF]

open access: yesPLoS One
Arelingaiah M   +19 more
europepmc   +1 more source

Causality assessment tool for drug‐induced acute kidney injury in patients admitted to intensive care units: Requirements from a multicentre retrospective study in the Netherlands reusing data from electronic health records

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to provide key requirements for a drug‐induced acute kidney injury (d‐AKI) causality assessment tool (CAT) for intensive care unit (ICU) patients, using vancomycin‐induced AKI (v‐AKI) as a test case. Methods A retrospective review was conducted by medical experts of electronic health records of ICU patients from 14 Dutch ICUs.
Joanna E. Klopotowska   +44 more
wiley   +1 more source

Economic evaluations of antiobesity medications: A systematic literature review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković   +5 more
wiley   +1 more source

Checklist

open access: yesJournal of the Formosan Medical Association, 2019
  +4 more sources

Long‐term cost‐effectiveness of belatacept vs. tacrolimus in kidney transplantation: Trade‐off between metabolic benefit and immunological risk

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the long‐term cost‐effectiveness of belatacept vs. tacrolimus as maintenance immunosuppression in adult kidney transplant recipients, focusing on the trade‐off between reduced new‐onset diabetes after transplantation (NODAT), immunological risk and potential renal benefit.
Salvatore Di Maria   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy